TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Techniques
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Impact on Supply Chain
5.3.3. Regional Impact
5.3.4. Opportunity and Threat Analysis
6. GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE
6.1. Overview
6.2. Sterile Drugs
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.3. Medical Devices
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.4. Biologics
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
7. GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE
7.1. Overview
7.2. Instruments
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
7.3. Kits & Reagents
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
7.4. Services
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
8. GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE
8.1. Overview
8.2. In-house
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
8.3. Outsourcing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
9. GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE
9.1. Overview
9.2. Sterility Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
9.3. Bioburden Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
9.4. Bacterial Endotoxin Testing
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
10. GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER
10.1. Overview
10.2. Compounding Pharmacies
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
10.3. Medical Devices Companies
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
10.4. Pharmaceutical Companies
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
10.5. Others
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
11. GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY REGION
11.1. Overview
11.2. North America
11.2.1. US
11.2.2. Canada
11.3. Europe
11.3.1. Germany
11.3.2. France
11.3.3. Italy
11.3.4. Spain
11.3.5. UK
11.3.6. Rest of Europe
11.4. Asia-Pacific
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Rest of the World
11.5.1. Middle East
11.5.2. Africa
11.5.3. Latin America
12. COMPANY LANDSCAPE
12.1. Overview
12.2. Competitive Analysis
12.3. Market Share Analysis
12.4. Major Growth Strategy in the Global Pharmaceutical Sterility Testing Market
12.5. Competitive Benchmarking
12.6. Leading Players in terms of Number of Developments in the Global Pharmaceutical Sterility Testing Market
12.7. Key developments and Growth Strategies
12.7.1. New Product Launch/Service Deployment
12.7.2. Mergers & Acquisitions
12.7.3. Joint Ventures
12.8. Major Players Financial Matrix
12.8.1. Sales & Operating Income, 2020
12.8.2. Major Players R&D Expenditure, 2020
13. COMPANY PROFILES
13.1. Merck KGaA
13.1.1. Company Overview
13.1.2. Key Financials
13.1.3. Products Offered
13.1.4. Key Developments
13.1.5. SWOT Analysis
13.1.6. Key Strategies
13.2. Rapid Micro Biosystems
13.2.1. Company Overview
13.2.2. Key Financials
13.2.3. Products Offered
13.2.4. Key Developments
13.2.5. SWOT Analysis
13.2.6. Key Strategies
13.3. Sartorius AG
13.3.1. Company Overview
13.3.2. Key Financials
13.3.3. Products Offered
13.3.4. Key Developments
13.3.5. SWOT Analysis
13.3.6. Key Strategies
13.4. Solvias AG
13.4.1. Company Overview
13.4.2. Key Financials
13.4.3. Products Offered
13.4.4. Key Developments
13.4.5. SWOT Analysis
13.4.6. Key Strategies
13.5. SGS SA
13.5.1. Company Overview
13.5.2. Key Financials
13.5.3. Products Offered
13.5.4. Key Developments
13.5.5. SWOT Analysis
13.5.6. Key Strategies
13.6. Boston Analytical
13.6.1. Company Overview
13.6.2. Key Financials
13.6.3. Products Offered
13.6.4. Key Developments
13.6.5. SWOT Analysis
13.6.6. Key Strategies
13.7. BioMérieux, Inc.
13.7.1. Company Overview
13.7.2. Key Financials
13.7.3. Products Offered
13.7.4. Key Developments
13.7.5. SWOT Analysis
13.7.6. Key Strategies
13.8. Charles River Laboratories International, Inc.
13.8.1. Company Overview
13.8.2. Key Financials
13.8.3. Products Offered
13.8.4. Key Developments
13.8.5. SWOT Analysis
13.8.6. Key Strategies
13.9. Thermo Fisher Scientific, Inc.
13.9.1. Company Overview
13.9.2. Key Financials
13.9.3. Products Offered
13.9.4. Key Developments
13.9.5. SWOT Analysis
13.9.6. Key Strategies
13.10. Pace Analytical Services, LLC
13.10.1. Company Overview
13.10.2. Key Financials
13.10.3. Products Offered
13.10.4. Key Developments
13.10.5. SWOT Analysis
13.10.6. Key Strategies
13.11. Toxikon, Inc.
13.11.1. Company Overview
13.11.2. Key Financials
13.11.3. Products Offered
13.11.4. Key Developments
13.11.5. SWOT Analysis
13.11.6. Key Strategies
13.12. Sotera Health
13.12.1. Company Overview
13.12.2. Key Financials
13.12.3. Products Offered
13.12.4. Key Developments
13.12.5. SWOT Analysis
13.12.6. Key Strategies
13.13. Pacific Biolabs Inc.
13.13.1. Company Overview
13.13.2. Key Financials
13.13.3. Products Offered
13.13.4. Key Developments
13.13.5. SWOT Analysis
13.13.6. Key Strategies
13.14. STRERIS Corporation
13.14.1. Company Overview
13.14.2. Key Financials
13.14.3. Products Offered
13.14.4. Key Developments
13.14.5. SWOT Analysis
13.14.6. Key Strategies
13.15. WuXi AppTec
13.15.1. Company Overview
13.15.2. Key Financials
13.15.3. Products Offered
13.15.4. Key Developments
13.15.5. SWOT Analysis
13.15.6. Key Strategies
14. APPENDIX
14.1. References
14.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SYNOPSIS, 2022–2030
TABLE 2 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET ESTIMATES & FORECAST, 2022– 2030 (USD MILLION)
TABLE 3 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 4 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 5 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 6 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 7 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 8 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 9 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 10 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 11 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 12 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 13 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 14 US: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 15 US: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 16 US: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 17 US: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 18 US: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 19 CANADA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 20 CANADA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 21 CANADA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 22 CANADA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 23 CANADA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 24 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 25 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 26 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 27 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 28 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 29 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 30 GERMANY: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 31 GERMANY: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 32 GERMANY: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 33 GERMANY: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 34 GERMANY: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 35 FRANCE: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 36 FRANCE: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 37 FRANCE: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 38 FRANCE: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 39 FRANCE: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 40 ITALY: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 41 ITALY: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 42 ITALY: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 43 ITALY: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 44 ITALY: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 45 SPAIN: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 46 SPAIN: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 47 SPAIN: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 48 SPAIN: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 49 SPAIN: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 50 UK: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 51 UK: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 52 UK: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 53 UK: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 54 UK: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 55 REST OF EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 56 REST OF EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 57 REST OF EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 58 REST OF EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 59 REST OF EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 60 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 61 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 62 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 63 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 64 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 65 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 66 JAPAN: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 67 JAPAN: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 68 JAPAN: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 69 JAPAN: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 70 JAPAN: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 71 CHINA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 72 CHINA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 73 CHINA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 74 CHINA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 75 CHINA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 76 INDIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 77 INDIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 78 INDIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 79 INDIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 80 INDIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 81 AUSTRALIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 82 AUSTRALIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 83 AUSTRALIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 84 AUSTRALIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 85 AUSTRALIA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 86 SOUTH KOREA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 87 SOUTH KOREA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 88 SOUTH KOREA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 89 SOUTH KOREA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 90 SOUTH KOREA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 91 REST OF ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 92 REST OF ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 93 REST OF ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 94 REST OF ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 95 REST OF ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 96 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET, BY REGION, 2022–2030 (USD MILLION)
TABLE 97 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 98 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 99 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 100 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 101 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 102 MIDDLE EAST: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 103 MIDDLE EAST: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 104 MIDDLE EAST: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 105 MIDDLE EAST: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 106 MIDDLE EAST: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 107 AFRICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 108 AFRICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 109 AFRICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 110 AFRICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 111 AFRICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 112 LATIN AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY SAMPLE, 2022–2030 (USD MILLION)
TABLE 113 LATIN AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION)
TABLE 114 LATIN AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TYPE, 2022–2030 (USD MILLION)
TABLE 115 LATIN AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
TABLE 116 LATIN AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET, BY END USER, 2022–2030 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET
FIGURE 4 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY SAMPLE, 2020 (%)
FIGURE 5 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY PRODUCT TYPE, 2020 (%)
FIGURE 6 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY TYPE, 2020 (%)
FIGURE 7 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY TEST TYPE, 2020 (%)
FIGURE 8 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY END USER, 2020 (%)
FIGURE 9 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 NORTH AMERICA: PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY REGION, 2020 (%)
FIGURE 11 EUROPE: PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY REGION, 2020 (%)
FIGURE 12 ASIA-PACIFIC: PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY REGION, 2020 (%)
FIGURE 13 REST OF THE WORLD: PHARMACEUTICAL STERILITY TESTING MARKET SHARE, BY REGION, 2020 (%)
FIGURE 14 GLOBAL PHARMACEUTICAL STERILITY TESTING MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 15 MERCK KGAA PHARMACEUTICALS: FINANCIAL OVERVIEW
FIGURE 16 MERCK KGAA PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 17 RAPID MICRO BIOSYSTEMS: FINANCIAL OVERVIEW
FIGURE 18 RAPID MICRO BIOSYSTEMS: SWOT ANALYSIS
FIGURE 19 SARTORIUS AG: FINANCIAL OVERVIEW
FIGURE 20 SARTORIUS AG: SWOT ANALYSIS
FIGURE 21 SOLVIAS AG: FINANCIAL OVERVIEW
FIGURE 22 SOLVIAS AG: SWOT ANALYSIS
FIGURE 23 SGS SA: FINANCIAL OVERVIEW
FIGURE 24 SGS SA: SWOT ANALYSIS
FIGURE 25 BOSTON ANALYTICAL: FINANCIAL OVERVIEW
FIGURE 26 BOSTON ANALYTICAL: SWOT ANALYSIS
FIGURE 27 BIOMÉRIEUX, INC.: FINANCIAL OVERVIEW
FIGURE 28 BIOMÉRIEUX, INC.: SWOT ANALYSIS
FIGURE 29 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: FINANCIAL OVERVIEW
FIGURE 30 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: SWOT ANALYSIS
FIGURE 31 THERMO FISHER SCIENTIFIC, INC.: FINANCIAL OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: SWOT ANALYSIS
FIGURE 33 PACE ANALYTICAL SERVICES, LLC: FINANCIAL OVERVIEW
FIGURE 34 PACE ANALYTICAL SERVICES, LLC: SWOT ANALYSIS
FIGURE 35 TOXIKON, INC.: FINANCIAL OVERVIEW
FIGURE 36 TOXIKON, INC.: SWOT ANALYSIS
FIGURE 37 SOTERA HEALTH: FINANCIAL OVERVIEW
FIGURE 38 SOTERA HEALTH: SWOT ANALYSIS
FIGURE 39 PACIFIC BIOLABS INC.: FINANCIAL OVERVIEW
FIGURE 40 PACIFIC BIOLABS INC.: SWOT ANALYSIS
FIGURE 41 STRERIS CORPORATION: FINANCIAL OVERVIEW
FIGURE 42 STRERIS CORPORATION: SWOT ANALYSIS
FIGURE 43 WUXI APPTEC: FINANCIAL OVERVIEW
FIGURE 44 WUXI APPTEC: SWOT ANALYSIS